BR112021026395A2 - Compostos de 2,3-di-hidroquinazolina como inibidores de nav1.8 - Google Patents
Compostos de 2,3-di-hidroquinazolina como inibidores de nav1.8Info
- Publication number
- BR112021026395A2 BR112021026395A2 BR112021026395A BR112021026395A BR112021026395A2 BR 112021026395 A2 BR112021026395 A2 BR 112021026395A2 BR 112021026395 A BR112021026395 A BR 112021026395A BR 112021026395 A BR112021026395 A BR 112021026395A BR 112021026395 A2 BR112021026395 A2 BR 112021026395A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- inhibitors
- dihydroquinazoline
- methods
- pain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
compostos de 2,3-di-hidroquinazolina como inibidores de nav1.8. a presente invenção refere-se aos compostos de inibidor 2,3-di-hidroquinazolina de nav1.8 da fórmula (x)em que y, x, b, r1, r2, r3, r5, r6, r7 e z1 são definidos neste relatório; ou sais farmaceuticamente aceitáveis ou formas tautoméricas dos mesmos, composições farmacêuticas ou formulações correspondentes, métodos ou processos de preparação de compostos, métodos, compostos para o uso em, usos para e/ou terapias de combinação para tratar dor e/ou doenças, transtornos ou condições associadas ou relacionadas à dor, respectivamente.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962867714P | 2019-06-27 | 2019-06-27 | |
US201962896698P | 2019-09-06 | 2019-09-06 | |
PCT/IB2020/055921 WO2020261114A1 (en) | 2019-06-27 | 2020-06-23 | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021026395A2 true BR112021026395A2 (pt) | 2022-02-08 |
Family
ID=71738221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021026395A BR112021026395A2 (pt) | 2019-06-27 | 2020-06-23 | Compostos de 2,3-di-hidroquinazolina como inibidores de nav1.8 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230103791A1 (pt) |
EP (1) | EP3990436A1 (pt) |
JP (1) | JP2022538588A (pt) |
KR (1) | KR20220030257A (pt) |
CN (1) | CN114040911A (pt) |
AU (2) | AU2020302338A1 (pt) |
BR (1) | BR112021026395A2 (pt) |
CA (1) | CA3142902A1 (pt) |
CL (1) | CL2021003477A1 (pt) |
CO (1) | CO2022000480A2 (pt) |
IL (1) | IL288236A (pt) |
MA (1) | MA56398A (pt) |
MX (1) | MX2021015605A (pt) |
TW (1) | TW202114995A (pt) |
WO (1) | WO2020261114A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023554430A (ja) * | 2020-12-18 | 2023-12-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Nav1.8阻害剤としての含窒素2,3-ジヒドロキナゾリノン化合物 |
WO2022256676A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
EP4346818A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
CN117813302A (zh) | 2021-06-04 | 2024-04-02 | 沃泰克斯药物股份有限公司 | 经取代的四氢呋喃-2-甲酰胺作为钠通道调节剂 |
WO2022256842A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
AU2022286438A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
IL308953A (en) | 2021-06-04 | 2024-01-01 | Vertex Pharma | N-Hydroalkyl(Hetero)Aryl)Tetrahydrofuran Carboxamides as Natrene Channel Modulators |
AR126669A1 (es) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
AR126670A1 (es) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
WO2023164596A1 (en) * | 2022-02-25 | 2023-08-31 | The Katholieke Universiteit Leuven | Dihydroquinazolinones and related analogs for inhibiting yap/taz-tead |
CN114605408B (zh) * | 2022-03-30 | 2023-06-16 | 沈阳药科大学 | 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用 |
US20230373925A1 (en) | 2022-04-22 | 2023-11-23 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023211990A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
TW202400560A (zh) * | 2022-04-28 | 2024-01-01 | 南韓商愛思開生物製藥股份有限公司 | N-氧化物化合物及其用途 |
WO2023238065A1 (en) * | 2022-06-09 | 2023-12-14 | Glaxosmithkline Intellectual Property Development Limited | Nitrogen containing condensed 2,3-dihydroquinazolinone compounds as nav1.8 inhibitors |
US20230416287A1 (en) | 2022-06-09 | 2023-12-28 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3761480A (en) * | 1968-07-10 | 1973-09-25 | Pennwalt Corp | Process for the preparation of 3-aryl-6-sulfamyl-7-halo-1,2,3,4-tetrahydro-4-quinazolinones |
US7713983B2 (en) * | 2003-03-03 | 2010-05-11 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
ZA200507979B (en) * | 2003-03-03 | 2007-03-28 | Vertex Pharma Inc | Quinazolines useful as modulators of ion channels |
US7767680B2 (en) * | 2004-11-03 | 2010-08-03 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
EP2035406A4 (en) * | 2006-07-05 | 2009-08-05 | Korea Res Inst Chem Tech | NEW SUBSTITUTED 1H-CHINAZOLIN-2,4-DION DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEM |
AR065081A1 (es) * | 2007-01-29 | 2009-05-13 | Xenon Pharmaceuticals Inc | Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica |
NZ710111A (en) * | 2013-01-31 | 2020-08-28 | Vertex Pharma | Quinoline and quinoxaline amides as modulators of sodium channels |
US20190134056A1 (en) * | 2017-03-10 | 2019-05-09 | The Trustees Of The Stevens Institute Of Technolog | K-ras mutations and antagonists |
-
2020
- 2020-06-23 WO PCT/IB2020/055921 patent/WO2020261114A1/en active Application Filing
- 2020-06-23 US US17/617,479 patent/US20230103791A1/en active Pending
- 2020-06-23 JP JP2021577097A patent/JP2022538588A/ja active Pending
- 2020-06-23 CA CA3142902A patent/CA3142902A1/en active Pending
- 2020-06-23 EP EP20743811.0A patent/EP3990436A1/en active Pending
- 2020-06-23 AU AU2020302338A patent/AU2020302338A1/en not_active Abandoned
- 2020-06-23 BR BR112021026395A patent/BR112021026395A2/pt unknown
- 2020-06-23 MA MA056398A patent/MA56398A/fr unknown
- 2020-06-23 MX MX2021015605A patent/MX2021015605A/es unknown
- 2020-06-23 KR KR1020227002579A patent/KR20220030257A/ko unknown
- 2020-06-23 CN CN202080047250.4A patent/CN114040911A/zh active Pending
- 2020-06-24 TW TW109121445A patent/TW202114995A/zh unknown
-
2021
- 2021-11-18 IL IL288236A patent/IL288236A/en unknown
- 2021-12-24 CL CL2021003477A patent/CL2021003477A1/es unknown
-
2022
- 2022-01-20 CO CONC2022/0000480A patent/CO2022000480A2/es unknown
-
2023
- 2023-11-20 AU AU2023270195A patent/AU2023270195A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20220030257A (ko) | 2022-03-10 |
CA3142902A1 (en) | 2020-12-30 |
AU2020302338A1 (en) | 2022-01-27 |
CN114040911A (zh) | 2022-02-11 |
CL2021003477A1 (es) | 2023-04-21 |
EP3990436A1 (en) | 2022-05-04 |
AU2023270195A1 (en) | 2023-12-14 |
US20230103791A1 (en) | 2023-04-06 |
MX2021015605A (es) | 2022-02-16 |
JP2022538588A (ja) | 2022-09-05 |
MA56398A (fr) | 2022-05-04 |
WO2020261114A1 (en) | 2020-12-30 |
IL288236A (en) | 2022-01-01 |
TW202114995A (zh) | 2021-04-16 |
CO2022000480A2 (es) | 2022-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021026395A2 (pt) | Compostos de 2,3-di-hidroquinazolina como inibidores de nav1.8 | |
BR112016015983A2 (pt) | Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica | |
UY37795A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
BR112017028504A2 (pt) | derivados de sulfamoilarilamida ciclizada e uso dos mesmos como medicamentos para o tratamento da hepatite b | |
BR112018000624A2 (pt) | compostos de indazol e azaindazol como inibidores de irak-4 | |
BR112018008966A2 (pt) | compostos inibidores de jak quinase para o tratamento de doença respiratória | |
BR112018074185A2 (pt) | 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas | |
BR112016023679A2 (pt) | derivados de amida e sais farmaceuticamente aceitáveis dos mesmos, método de preparação dos mesmos e aplicação medicinal dos mesmos | |
BR112015016395A2 (pt) | pirazóis 3-substituídos e uso como inibidores de dlk | |
BR112018071216A2 (pt) | inibidores de bromodomínios | |
BR112016029916A2 (pt) | inibidores mnk e métodos correlatos | |
BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
BR112017002942A2 (pt) | compostos e derivados de espiro[3h-indol-3,2´-pirrolidin]2(1h)-ona como inibidores de mdm2-p53 | |
BR112016017996A2 (pt) | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso | |
BR112019025049A2 (pt) | Anéis 6- 5 fundidos como inibidores de c5a | |
BR112019004248A2 (pt) | inibidores da dopamina-b-hidroxilase | |
BR112022006018A2 (pt) | Heteroaril-bifenil amidas para o tratamento de doenças relacionadas à pd-l1 | |
PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
BR112021006319A2 (pt) | compostos de indolinona para uso como inibidores de map4k1 | |
BR112019003320A2 (pt) | compostos de heteroaril carboxamida como inibidores de ripk2 | |
EA202191188A1 (ru) | Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения | |
BR112022006279A2 (pt) | Heteroaril-bifenil aminas para o tratamento de doenças pd-l1 | |
BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
BR112021011325A2 (pt) | Derivados de rapamicina |